RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond. Wu J, Subbiah V. Cancer Res 2023;83:3159-3161.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Wu J, Subbiah V. RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond. Cancer Res 2023;83:3159-3161.
PMID: 37779428